Pristinamycin: old drug, new tricks?

被引：23

作者：

Cooper, Eden C. ^{[1
,2
]}

Curtis, Nigel ^{[1
,2
,3
]}

Cranswick, Noel ^{[1
,2
,3
]}

Gwee, Amanda ^{[2
,3
]}

机构：

[1] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia

[2] Royal Childrens Hosp Melbourne, Infect Dis & Clin Pharmacol Unit, Dept Med, Melbourne, Vic, Australia

[3] Murdoch Childrens Res Inst, Parkville, Vic, Australia

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2014年 / 69卷 / 09期

关键词：

quinupristin/dalfopristin; streptogramin; Gram positive infections; bone and joint infections; osteomyelitis; arthritis; prosthesis infections; STAPHYLOCOCCUS-AUREUS MRSA; ANTIBIOTIC-TREATMENT; ORAL PRISTINAMYCIN; JOINT INFECTIONS; INVITRO ACTIVITY; THERAPY; OSTEOMYELITIS; MANAGEMENT; OXACILLIN; TRIAL;

D O I：

10.1093/jac/dku167

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Osteoarticular infections with Gram positive bacteria present an increasing challenge in an era of multidrug-resistant organisms. Prolonged intravenous antibiotic treatment is often required, with associated risks, costs and difficulties with administration; a safe, effective oral option would be ideal for this indication. Pristinamycin, an oral streptogramin antibiotic with bactericidal activity against Gram positive organisms including methicillin-resistant Staphylococcus aureus, has been used for over 50 years in Europe for the treatment of osteoarticular infections. We review the published evidence for the treatment of native bone and prosthesis-related osteoarticular infections with pristinamycin.

引用

页码：2319 / 2325

页数：7